COMMUNIQUÉS West-GlobeNewswire

Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
07/04/2026
Mr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice President, Sales at Arcutis Biotherapeutics (Nasdaq: ARQT), where he led U.S. sales efforts for [...]
electroCore Announces First Patient Enrollment in Investigator-Led Study of gammaCore™ nVNS for PTSD
07/04/2026
ROCKAWAY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the enrollment of the first eight patients in a [...]
SS Innovations to Host SMRSC 2026 in New Delhi, India from April 9-11, 2026
07/04/2026
Conference to Unite Global Leaders at the Forefront of Surgical Robotic Innovation FORT LAUDERDALE, Fla., April 07, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq [...]
Integra LifeSciences Unveils New Real-World Evidence Highlighting PriMatrix® Utilization
07/04/2026
Results to be featured at Functional Diabetic Limb Salvage, Society of Advanced Wound Care and American Burn Association Conferences in April PRINCETON, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences [...]
Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness
07/04/2026
New product offerings and educational initiative, Ready to Rescue, aim to increase access and adoption of NARCAN® Nasal Spray to empower communities to save a life in an opioid overdose emergency GAITHERSBURG, Md., [...]
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting
07/04/2026
Five abstracts accepted including Late-breaking Science oral and poster presentations of Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures Poster presentations also include long-term efficacy and [...]
Route 92 Medical Announces $50 Million Growth Financing
07/04/2026
New investor Sectoral Asset Management joins growth financing round to support acceleration of commercial growth WEST JORDAN, Utah, April 07, 2026 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical [...]
Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board
07/04/2026
New Advisors Bring Nationwide Pharmacy and Wellness Distribution Expertise to Nugevia ™ Consumer Longevity Line Compounding Pharmacy and Wellness Channels Represent Over $1.5 Billion Addressable Market for Practitioner- [...]
Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference
07/04/2026
SOUTH SAN FRANCISCO, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell [...]
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
07/04/2026
WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial [...]
Virbac : Déclaration d'actions et de droits de votes 03/2026
07/04/2026
DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Oculis to Participate in Upcoming Investor Conferences
07/04/2026
ZUG, Switzerland, April 07, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro- [...]
SonoNeu exits stealth as key part of US Government-funded research program worth up to $41.3m to advance sonogenetics into clinic
07/04/2026
Sonogenetics, discovered by SonoNeu founder Sreekanth Chalasani, is a new modality using ultrasound to precisely control specific cells ‘tagged’ with special proteins SonoNeu is part of a collaborative project, also [...]
Transactions in connection with share buy-back program
07/04/2026
Company announcement no. 9 - 26 07 April 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
07/04/2026
COPENHAGEN, Denmark, April 7, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up to [...]
Virbac : Declaration of the number of shares and voting rights 03/2026
07/04/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
SPINEWAY : Compte-rendu de l’Assemblée Générale du 2 avril 2026
07/04/2026
Ecully, le 7 avril 2026 – 8h00 SPINEWAY Compte-rendu de l’Assemblée Générale du 2 avril 2026 L'Assemblée Générale Mixte (Ordinaire et Extraordinaire) des actionnaires de Spineway s'est tenue sur première convocation ce [...]
Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP
07/04/2026
Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate-to-severe asthma [...]
Communiqué de presse: Le lunsekimig de Sanofi a atteint les critères d’évaluation principal et secondaires clés dans les études respiratoires de phase 2 dans l’asthme et la rhinosinusite chronique avec polypose nasale
07/04/2026
Le lunsekimig de Sanofi a atteint les critères d’évaluation principal et secondaires clés dans les études respiratoires de phase 2 dans l’asthme et la rhinosinusite chronique avec polypose nasale L’étude de phase 2b [...]

Pages